What is pathophysiology of Lung cancer?

['Welisi hɔɔlʋʋ kʋnɛ']

Ɛbɛ payaɣ se cancer du poumon?

Kʋdɔŋ piye nɖɩ ɖɩ-tɛ maɣzɩm wɛ ndɩ nɛ calɩm taa maɣzɩm mbʊ pʊyɔɔ yɔ ɖɩ-tɛ maɣzɩm wɛ ndɩ nɛ calɩm taa maɣzɩm mbʊ pʊyɔɔ yɔ ɖɩ-tɛ maɣzɩm wɛ ndɩ nɛ calɩm taa maɣzɩm mbʊ.

Kʋdɔŋ piye nɖɩ ɖɩlɩna ɛzɩma calɩm kpeŋ nɛ pɩɖɛɣna nɛ pɩɖɛɣna awayɩ yɔ.

Pɩpɩzɩɣ piyele nɛ tomnaɣ hɔɔlɩŋ lɛɛŋ taa ɖɔɖɔ kʋdɔmɩŋ nɩɩyɩ lɩɩ.

Kʊdɔŋ ŋgʊ kɩɖɛʊ yɔ kɩlɩna hɔɔlɩŋ ndɩ ndɩ cɔlɔ, ɛzɩ calɩm taa kʊdɔmɩŋ, tɛtʊ yɔɔ wondu nɛ wezuu caɣʊ.

Pɩpɩzɩɣ piyele nɛ calɩm tootoye nɖɩ ɖɩwɛ kpeziwɩlaɣ taa yɔ ɖɩpaɣzɩ cɛbʋ.

Pɩpɩzɩɣ nɛ pɩlɩɩnɩ ɛzɩma ɛyʋ cakɩ wezuu nɛ ɛñɔʋ tabakʋʋyaɣ yɔ, mbʋ payaɣ se radon, asbestos, nɛ helim mbʋ pipisiɣ tomnaɣ yɔ.

Kʊdɔŋ ŋgʊ kɩ-tɛ calɩm taa wɛna calɩm fɩɣa cikpelaɣ (cancer du poumon à petites cellules) nɛ ŋgʊ kɩ-tɛ calɩm fɩɣa cikpelaɣ fɛyɩ (cancer du poumon non à petites cellules) nɛ pɩtasɩna pɩ-tɛ calɩm fɩɣa cikpelaɣ ŋga kɛwɛna calɩm fɩɣa cikpelaɣ fɛyɩ yɔ.

Kʊdɔmɩŋ weyi ɩlɩna feziŋ kɩdɛkɛdɩŋ ɛnʊ ɛ-tɛ yɔ, ɩpɩzɩɣ ɩwɛɛ ndɩ ndɩ, mbʊ pʊyɔɔ yɔ, ɛyʊ tomnaɣ taa calɩm wɛ ndɩ ndɩ nɛ ɛzɩma palakɩna-pʊ nɛ tʊmɩyɛ yɔ pɩwɛ ndɩ ndɩ.

Kʋdɔŋ piye nɖɩ ɖɩlɩɣnɩ calɩm taa yɔ, ɖɩ-taa wɛ calɩm fɩɣa ŋga payaɣ se lymphocyte yɔ nɛ calɩm fɩɣa ŋga payaɣ se lymphocyte yɔ.

Pɩpɩzɩɣ piyele nɛ kʋdɔmɩŋ pe wena awɛ kʋdɔmɩŋ pe ana a-taa yɔ, apaɣlɩ nɛ awɛɛkɩɣ ɛyaa sakɩyɛ.

Pɩtasɩ lɛ, kʋdɔŋ piye nɖɩ ɖɩ-tɛ wɛtʋ pɩzɩɣ nɛ tɩhaɣ waɖɛ nɛ ɖɩpaɣlɩɣ nɛ ɖɩɖɛɣ ɖɔɖɔ.

Kʊdɔŋ ŋgʊ kɩɖɛʊ yɔ kɩ-tɛ maɣzɩm wɛ ndɩ nɛ kɩ-tɛ ɖoŋ wɛ ndɩ nɛ ñɩnɩyaa wɛɛ nɛ pañakɩ pana se patɩlɩ ɛzɩma kɩɖɛʊ yɔ nɛ pana se kɩ-tɛ wazasɩ ɖɔɔ nɛ pɩsa nɛ pana ɛzɩma pawaɣ kʊdɔŋ ŋgʊ yɔ.

['Takayɩhatʋ ndʋ tɩtamsɩna \\ yɔ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.

Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.

Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.

Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .

Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .

Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.

['Tɔm ndʋ tɩ-yɔɔ ɖitisiɣ yɔ: ɖɔkɔtɔ']

['Ye ŋwobi intɛrnɛɛtɩ lone ɖɩnɛ ɖɩ-yɔɔ yɔ, ŋpɩzɩɣ nɛ ŋkpɛlɩkɩ tɔm sakɩyɛ ɖɩ-yɔɔ.']

['Pɩtɩpɔzɩ se patɩŋnɩ tɔm ndʋ pama takayaɣ kanɛ ka-taa yɔ tɩ-yɔɔ nɛ pañɩnɩ kʋdɔŋ nakʋyʋ yaa pawaa-kʋ.']

['Tɩlɩ camɩyɛ se ordinatɛɛrɩ yɔɔ tɔm ndʋ pɔpɔzʋʋ yɔ, tɩ-yɔɔ cosuu wɛ kaɖɛ, kɔzɩ kɔzɩ alɩwaatʋ ndʋ tɩ-taa pɔpɔzʋʋ tɔm natʋyʋ nɛ tɩ-taa tɔm pee tɩɖɔɔ yɔ.']

['Paa ɛzɩmtaa lɛ, pɔzɩ lɔŋ tasʋʋ fɛɖʋ weyi ɛsɩm ñɔ-yɔɔ tɔm sakɩyɛ yɔ nɛ ɛyɔɔdɩ-ŋ kʋdɔŋ ŋgʋ ŋwɛna yɔ kɩ-tɔm. Taayele nɛ lɔŋ tasʋʋ mbʋ fɛɖʋ ɛnʋ ɛha-ŋ yɔ, pɩɖɛɛ ñɔ-yɔɔ yaa ŋyele-pʋ ñɩnʋʋ mbʋ pʋyɔɔ yɔ ŋkalɩ tɔm natʋyʋ intɛrnɛɛtɩ lone ɖɩnɛ ɖɩ-yɔɔ. Ye ŋmaɣzɩɣ se pɩwɩɣ-ŋ yɔ, yaa ɛyaa 911 yaa ŋwolo ɖɔkɔtɔ ŋgʋ kɩñɔtɩnɩ-ŋ yɔ kɩ-taa kpaagbaa.']

['Takayɩhatʋ ndʋ tɩtamsɩna \\ Paɣtʋ \\ yɔ']

['Digital Millennium Copyright Act 1998 ñɩŋgʋ, 17 U.S.C. § 512 (DMCA) haɣ waɖɛ mba pɛwɛnɩ waɖɛ se pala tʋmɩyɛ intɛrnɛɛtɩ yɔɔ yɔ se pala mbʋ pɩkaɖɩɣnɩ waɖɛ nɖɩ pɛwɛna Etaazuunii ɛjaɖɛ taa yɔ.']

['Ye ŋmaɣzɩɣ se tɔm natʋyʋ yaa wonuu nakʋyʋ yɔɔ pama tɔm intɛrnɛɛtɩ lone ɖɩnɛ ɖɩ-yɔɔ yaa intɛrnɛɛtɩ lone ɖɩnɛ ɖɩ-yɔɔ nɛ pɩkaɖɩɣnɩ ña-paɣtʋ yɔ, ña-maɣmaɣ yaa weyi ɛsɩɣ-ŋ tʋmɩyɛ yɔ, ŋpɩzɩɣ nɛ ŋtiyini-ɖʋ takayaɣ nɛ ŋpɔzɩ se ɖɩlɩzɩ tɔm ndʋ yaa wonuu ŋgʋ yaa ɖitaayele nɛ nɔɔyʋ tɩlɩ-kʋ.']

['Pɩwɛɛ se pama takayaɣ nɛ petiyini ordinatɛɛrɩ yɔɔ.']

['DMCA paɣtʋ pɔzʋʋ se ye ŋnawa se nɔɔyʋ tɩma takayaɣ nakɛyɛ yɔ, ŋma tɔm tʋnɛ: (1) takayaɣ ŋga ŋnawa se nɔɔyʋ tɩma-kɛ yɔ kɔ-yɔɔ tɔm; (2) takayaɣ ŋga kɔ-yɔɔ pamawa se nɔɔyʋ tɩma takayaɣ nakɛyɛ yɔ kɔ-yɔɔ tɔm nɛ tɔm ndʋ tɩsɩɣnɩ-ɖʋ se ɖɩtɩlɩ ɖenɖe ŋnaɣ takayaɣ ŋga yɔ; (3) ña-hɩɖɛ, kaŋgalaafu mayaɣ nɛ intɛrnɛɛtɩ mayaɣ; (4) ŋyɔɔdɩ kpayɩ se ŋwɛnɩ tisuu se takayaɣ ŋga ŋnawa se nɔɔyʋ tɩma-kɛ yɔ, pɩtɩkɛ weyi ɛtɩnɩ takayaɣ ŋga yɔ ɛ-maɣmaɣ ɛlɩzɩnɩ-kɛ, yaa ɛ-tʋmlaɖʋ nɔɔyʋ lɩzɩnɩ-kɛ, yaa se paɣtʋ natʋyʋ ɛɛhaɣ nʋmɔʋ se palabɩnɩ-kɛ tʋmɩyɛ.']

['(5) Ye ŋlabɩ mbʋ yɔ, ŋpɩzɩɣ nɛ ŋcɛtɩnɩ ñɔ-tɔm yɔɔ nɛ ŋyɔɔdɩ se tɔm ndʋ pama takayaɣ ŋga ka-taa yɔ tɩkɛ toovenim nɛ ŋwɛnɩ waɖɛ se ŋlʋ nɛ ŋwa mba payʋsʋʋ se pɛwɛɛkɩ ña-takayaɣ yɔ.']

['Nɛ (6) ye nɔɔyʋ ɛtɩnɩ takayaɣ nakɛyɛ yɔɔ tɔm yɔ, pɩwɛɛ se ɛñɩɣ nesi takayaɣ ŋga kɔ-yɔɔ.']

['Ye patɩyɔɔdɩ tɔm ndʋ tɩ-tɩŋa yɔ, pɩpɩzɩɣ nɛ pɩkɔnɩ tɔm hʋʋ kaɖɛ.']

['Ɛyʋ weyi ŋkatɩɣ yɔ']

['Ye ŋwɛnɩ tɔm natʋyʋ yaa ŋñɩnɩɣ se ŋtasɩ tɔm natʋyʋ yɔ, ɖitendi-ŋ ma-ɖʋ takayaɣ.']

What is pathophysiology of lung cancer?

The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.

Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.

These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.

The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.

Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.

These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.

Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.

The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.

Cancer cells can evade the immune system, allowing them to grow and spread unchecked.

Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.

The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.